Immune-regulatory functions of Group 2 Innate Lymphoid cells in cancer

A specific type of immune cell—group 2 innate lymphoid cells (ILC2)—accumulates in precancerous pancreatic lesions as they turn into full-blown cancer in mice, and may also suppress the anti-tumour activity of natural killer (NK) cells in the lungs. This matters because current cancer immunotherapies focus almost entirely on "type-1" immune responses, such as those driven by cytotoxic T cells. But many tumours, including pancreatic cancer, are resistant to these treatments. The researchers suspect that ILC2s—immune cells normally linked to allergies—help create a pro-tumour environment. If confirmed, this would fill a major gap: no one has shown that ILC2s actively shape tumour growth, despite known links between the alarm signals that activate them and cancer progression. If the work succeeds, it could reveal a new target for cancer therapy. Blocking or reprogramming ILC2s might make immunotherapies effective against currently untreatable tumours, particularly pancreatic cancer and lung metastases. The project is fundamental science—it asks how a poorly understood immune cell behaves in cancer—but similar discoveries about immune checkpoints have already transformed oncology. A deeper understanding of ILC2s could open an entirely new axis for drug development.